
No results matched your search
(Reuters) - The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca (NASDAQ:AZN) Plc in children for the first time, it said on Saturday.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to an emailed statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a 'vaccine for the world' because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
By Carl O'Donnell (Reuters) - Novavax (NASDAQ:NVAX) Inc has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the...
By Sudipto Ganguly (Reuters) - World number two Daniil Medvedev of Russia has tested positive for COVID-19 and has been withdrawn from this week's Monte Carlo Masters, the ATP...
By Rocky Swift TOKYO (Reuters) - A health adviser to Japan's Olympic committee said on Tuesday athletes should have the option of getting COVID-19 vaccines, days after public...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.